Figure 1.
Trial profile
*88 patients received trametinib following disease progression. †One patient randomly assigned to the standard-of-care group received trametinib instead and was included in the safety analysis for the trametinib group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.